Small-Molecule Neutrophil Modulator ADS051 is Safe and Well-Tolerated in a Phase 1 Single Ascending Dose Study
ADS051 was safe, well-tolerated, and achieved high stool concentrations with minimal systemic exposure. ADS051 could be a safe and effective, locally acting, neutrophil-targeting agent for the treatment of UC.
Authors
- Bharat L. Dixit (ORCID: https://orcid.org/0009-0000-7028-5230)
- Benjamin Miller
- Ellie Hershberger
- Ronald Farquhar
- Adam S. Cheifetz (ORCID: https://orcid.org/0000-0002-6010-1896)
- Parviz Ghahramani
- Jessica R. Allegretti (ORCID: https://orcid.org/0000-0002-1175-1024)
- Christopher K. Murphy
- Megan Quintas
- A. Christopher Stevens (ORCID: https://orcid.org/0000-0001-6315-4160)
Institutions
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2024-11-26
- DOI
- https://doi.org/10.14309/ajg.0000000000003237
- Citations
- 1
- Primary Topic
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.24